204 results about "Stage melanoma" patented technology

The present invention is directed to the isolation and use of super-infective, tumor-specific vectors that are strains of parasites including, but not limited to bacteria, fungi and protists. In certain embodiments the parasites include, but are not limited to, the bacterium Salmonella spp., such as Salmonella typhimurium, the bacterium Mycobacterium avium and the protozoan Leishmania amazonensis. In other embodiments, the present invention is concerned with the isolation of super-infective, tumor-specific, suicide gene-containing strains of parasites for use in treatment of solid tumors.

A therapeutic agent for myeloma comprising a combined use of a nitrogen mustard anticancer agent and anti-IL-6 receptor antibody. Thus, a therapeutic agent for myeloma comprising anti-IL-6 receptor antibody for use in combination with a nitrogen mustard anticancer agent; a therapeutic agent for myeloma comprising a nitrogen mustard anticancer agent for use in combination with anti-IL-6 receptor antibody; and a therapeutic agent for myeloma comprising a nitrogen mustard anticancer agent and anti-IL-6 receptor antibody.

An immunotherapeutic vaccine providing antigen presenting cells that have been pulsed with a disrupted cell preparation which includes enucleated cytosol and cell membranes of cancer cells infected with a recombinant vaccinia virus encoding at least one immunostimulating molecule. In a preferred embodiment, the vaccine includes autologous dendritic / monocytic cells (DC / M) that present a mixture of antigens (present in the enucleated cytosol and cell membranes) from melanoma cell lines that have been infected with a recombinant vaccinia virus encoding IL-2. In another of the preferred embodiments, the enucleated cytosol and cell membranes are from melanoma cells harvested from the patient to be treated. A method of making the vaccine and methods of using the vaccine to stimulate an anti-cancer immune response and to treat a patient with a cancer are also described.

The present invention relates generally to polypeptides whose primary sequence has high sequence homology with human interleukin 2 (IL-2) with some punctual mutations in the sequence of native IL-2. The polypeptides of the present invention have an immunomodulatory effect on the immune system, which is selective / preferential on regulatory T cells. The present invention also relates to specific polypeptides whose amino acid sequence is disclosed herein. In another aspect the present invention relates to pharmaceutical compositions comprising as active ingredient the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptides and pharmaceutical compositions disclosed due to their immune modulating effect on diseases such as cancer and chronic infectious diseases.

The present invention pertains to certain imidazo[4,5-b]pyridin-2-one and oxazolo[4,5 b]pyridin-2-one compounds and analogs thereof, which, inter alia, inhibit RAF (e.g., B RAF) activity, inhibit cell proliferation, treat cancer, etc. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., B-RAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and conditions that are ameliorated by the inhibition of RAF, RTK, etc., proliferative conditions such as cancer (e.g., colorectal cancer, melanoma), etc.

The invention provides a quantitative realtime RT-PCR assay for detection of metastatic breast, gastric, pancreas or colon cancer cells or metastatic melanoma. The assay allows to predict disease recurrence and survival in patients with AJCC stage I and II, and III disease using multimarker panels. The method for detecting metastatic melanoma cells utilizes panels of markers selected from a group consisting of MAGE-A3, GalNAcT, MART-1, PAX3, Mitf, TRP-2, and Tyrosinase. The method for detecting metastatic breast, gastric, pancreas or colon cancer cells in paraffin-embedded samples utilizes panels of markers selected from a group consisting of C-Met, MAGE-A3, Stanniocalcin-1, mammoglobin, HSP27, GalNAcT, CK20, and β-HCG.

The present invention provides novel compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., cyclin-dependent kinase 7 (CDK7)), and therefore, induce cellular apoptosis and / or inhibit transcription in the subject. (I)

The present invention relates to methods for diagnosing, staging, prognosticating and treating melanoma based on evaluating the expression of specific patterns of oncogenic or suppressive microRNA (miR) molecules in a patient in need thereof.

The invention relates to the transformation of a chemical structure of a natural medicinal plant, namely ursolic acid, in particular to ursolic acid nitrogen heterocyclic ring structure modifiers with antitumor activity and a preparation method for the ursolic acid nitrogen heterocyclic ring structure modifiers. The ursolic acid nitrogen heterocyclic ring structure modifiers are ursolic acid nitrogen heterocyclic ring derivatives shown as a general formula (I). The preparation method comprises the following steps of: oxidizing or acetylating a C-3 hydroxyl group of the ursolic acid, performing condensation reaction of a C-17 carboxyl group and piperazine or a derivative of the piperazine so as to achieve the structural transformation of the ursolic acid, and thus obtaining a series of ursolic acid nitrogen heterocyclic ring structure modifiers. The in-vitro inhibitory activities of the ursolic acid nitrogen heterocyclic ring structure modifiers on human malignant melanoma A-375 cells, human gastric carcinoma AGS and BGC-823 cells are determined; and methyl thiazolyl tetrazolium (MTT) data show that the modifiers have a certain effect of inhibiting the proliferation of three kinds of cancer cells, and the inhibitory activity of partial compounds is even superior to that of paclitaxel.

The invention discloses a new application of the antitumor effect of a Miao ethnomedicine psammosilene tunicoids, and simultaneously discloses a preparation method and preparation of the pharmaceutical part of psammosilene tunicoids with the antitumor activity. The preparation method mainly comprises the steps of: extracting by ethanol, concentrating, extracting by n-butyl alcohol, purifying by macroporous absorption resin, and the like to obtain the total saponins of psammosilene tunicoids (TSPT). The total saponins are used as raw materials to prepare clinical commonly used pharmaceutical preparations such as tablets, capsules, injections and the like. A method of pharmacodynamic evaluation both in vivo and in vitro is adopted, wherein shown by in vitro tests, the TSPT has stronger inhibitory actions on 6 tumor cells of stomach cancer, liver cancer, colon cancer, ovarian cancer, breast cancer and melanoma, but has unobvious inhibition on the normal splenic lymphocyte; shown by integral animal in vivo experimental results, the TSPT has an inhibition rate as high as 72% on S180 solid tumors and has high action valence, but has small influence on the body weight of mice; and compared with a positive drug cis-platinum, the TSPT has lower side effect. Shown by the experimental results, the TSPT has strong anticancer valence, low side effect and the advantage of original innovation.

The present invention provides bispecific antibodies that bind to CD3 and tumor antigens and methods of using the same. According to certain embodiments, the bispecific antibodies of the invention exhibit reduced effector functions and have a unique binding profile with regard to Fcγ receptors. The bispecific antibodies are engineered to efficiently induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, a second antigen-binding molecule that specifically binds human CD20, and an Fc domain that binds Fcγ receptors with a specific binding pattern. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell or melanoma tumors expressing CD20. The bispecific antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders.

Disclosed are chelating agent-conjugated α-MSH peptide derivatives, preparation methods thereof, and compositions for use in a diagnosis or treatment of a melanoma tumor containing the same as an active ingredient. The novel α-MSH peptide derivatives conjugated with chelating agent according to the present invention are highly selective to the melanocortin-1 receptor which is α-MSH receptor expressing in melanoma tumor and their labeling rate of a radioactive isotope is high. Also, they remain in kidney shortly and have high taking rate of the melanoma tumor. Therefore, with the aforesaid reasons, they may be effectively used for early diagnosis or treatment of melanoma tumor.